NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...

Novo Nordisk today announced a collaboration with the American Society of Haematology (ASH) to support the Consortium on Newborn Screening in Africa (CONSA) Community Health Worker (CHW) Initiative.

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

NVIDIA Corporation (NASDAQ:NVDA) is one of the. NVIDIA Corporation (NASDAQ:NVDA) announced a collaboration with Novo Nordisk ...